US · Healthcare · Medical Devices
EPS came in at -0.09 against a street estimate of -0.06 — a miss of 50.0%.
Analysts rate Cytek Biosciences Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $5.56.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.37% |
| Millennium Management LLC | 7.18% |
| Boston Partners Global Investors, Inc | 5.89% |
| Hillhouse Capital Advisors, Ltd. | 5.12% |
| Topline Capital Management LLC | 4.83% |
| Vanguard Capital Management, LLC | 3.80% |
| Geode Capital Management, LLC | 2.35% |
| Dimensional Fund Advisors, Inc. | 2.01% |
| Document | Date |
|---|---|
| Charter / bylaws change · Q3 2026 OTHER NOTABLE POINTS • On September 23, 2026, Cytek Biosciences’ board unanimously adopted amended and restated bylaws, effective immediately. • The | 2026-09-29 |
| Reg FD disclosure · Q3 2026 CYTEK BIOSCIENCES, INC. — 8-K SUMMARY HEADLINE NUMBERS • Patent infringement lawsuit verdict issued August 21, 2026 in U.S. District Court for the D | 2026-08-24 |
| Quarterly report · Q2 2026 CYTEK BIOSCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $48.1 million (Q2 2025: $45.6 million) — 5.6% year-over-yea | 2026-08-05 |
| Results announced · Q3 2026 CYTEK BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $48.1 million — 6% increase versus Q2 2025 ($45.6 mill | 2026-08-05 |
| Board / officer change · Q3 2026 CYTEK BIOSCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • Chief Legal Officer Valerie Barnett's position terminated on June 29, 2026 • Severance paym | 2026-07-15 |
| Board / officer change · Q2 2026 CYTEK BIOSCIENCES, INC. – 8-K SUMMARY OTHER NOTABLE POINTS • Chief Legal Officer departure: Valerie Barnett, serving as Chief Legal Officer and Corp | 2026-06-25 |
| Quarterly report · Q1 2026 CYTEK BIOSCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $44.1 million (Product: $28.8M, Service: $15.4M) vs. Q1 2025: $41 | 2026-05-07 |
| Proxy statement · Q2 2026 CYTEK BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO TOTAL COMPENSATION & CHANGES • CEO (Faizan Ali) total compensation for 2025: Not exp | 2026-04-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cytek Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.